Zacks: Analysts Expect Agenus Inc. (NASDAQ:AGEN) Will Post Quarterly Sales of $17.35 Million

Analysts forecast that Agenus Inc. (NASDAQ:AGENGet Rating) will report $17.35 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Agenus’ earnings. The highest sales estimate is $19.70 million and the lowest is $15.00 million. Agenus posted sales of $11.72 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 48%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Agenus will report full-year sales of $63.04 million for the current fiscal year, with estimates ranging from $50.00 million to $79.13 million. For the next financial year, analysts expect that the company will post sales of $113.50 million, with estimates ranging from $94.50 million to $150.80 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Agenus.

Agenus (NASDAQ:AGENGet Rating) last issued its earnings results on Tuesday, March 1st. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10). The firm had revenue of $20.26 million for the quarter, compared to analyst estimates of $37.73 million. During the same quarter in the previous year, the business posted ($0.20) EPS.

Several equities research analysts have commented on AGEN shares. HC Wainwright boosted their price target on shares of Agenus from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 2nd. Zacks Investment Research lowered Agenus from a “hold” rating to a “sell” rating in a research report on Friday, March 4th. StockNews.com initiated coverage on Agenus in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, B. Riley reduced their price objective on shares of Agenus from $11.00 to $8.00 in a research note on Thursday, March 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.75.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its stake in Agenus by 37.2% in the third quarter. Goldman Sachs Group Inc. now owns 1,250,510 shares of the biotechnology company’s stock valued at $6,565,000 after purchasing an additional 339,057 shares in the last quarter. Chilton Capital Management LLC boosted its position in Agenus by 26.6% during the 3rd quarter. Chilton Capital Management LLC now owns 21,175 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 4,450 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Agenus in the 4th quarter valued at about $155,000. Millennium Management LLC increased its position in shares of Agenus by 2.7% during the 3rd quarter. Millennium Management LLC now owns 5,791,454 shares of the biotechnology company’s stock worth $30,405,000 after purchasing an additional 154,875 shares during the last quarter. Finally, AXA S.A. acquired a new position in Agenus during the third quarter worth $131,000. 47.60% of the stock is owned by institutional investors.

Shares of AGEN stock opened at $2.08 on Friday. The firm has a market capitalization of $534.88 million, a price-to-earnings ratio of -11.56 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.12 and a quick ratio of 2.12. Agenus has a 12-month low of $2.05 and a 12-month high of $6.79. The business has a 50 day simple moving average of $2.63 and a 200 day simple moving average of $3.23.

About Agenus (Get Rating)

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Further Reading

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.